IMGS-203

About ImmunoGenesis

ImmunoGenesis is targeting a critical unmet need in oncology: the majority of solid tumors are immune-excluded ('cold') and do not respond to first-generation PD-1/PD-L1 inhibitors. The company's core strategy involves engineering multifunctional, cytotoxic immune checkpoint inhibitors that combine best-in-class PD-1 pathway blockade with mechanisms to eliminate suppressive cells and reverse immunosuppressive barriers. Its lead asset, IMGS-001, is a first-in-class antibody designed to block both PD-L1 and PD-L2 while actively destroying tumor-protective cells, aiming to establish a new foundational monotherapy for cold tumors.

Therapeutic Areas

Other Not specified (Oncology) Drugs